Core Insights - THEON International Plc has inaugurated its fully owned subsidiary, THEON Belgium, and a new production facility in Zaventem, Belgium, marking a significant step in the company's European expansion [9] - The facility represents a multi-million-euro investment aimed at strengthening THEON's position as a leading European defense technology company with an international reach [10] - The facility will produce the IRIS-C thermal imaging clip-on system for the Belgian and German Armed Forces under a pan-European OCCAR IRCOD framework contract, with an initial order valued at approximately €50 million and an option for an additional €150 million [11] Company Developments - THEON Belgium was established on July 29, 2025, and has formed cooperation agreements with leading Belgian manufacturers in the electro-optic, metal, and electronics sectors [12] - The investment is expected to enhance local production, bolster supply chain resilience, create tech-driven jobs, and improve European production capacity [12] - The CEO of THEON emphasized the importance of joint procurement programs to strengthen Europe's operational readiness and industrial value [13] Industry Context - The establishment of the new facility is seen as a meaningful addition to Belgium's defense industrial base, leveraging domestic capabilities and contributing to closer defense cooperation across Europe [13] - The investment aligns with the rising global demand for THEON's A.R.M.E.D. product line, reflecting the company's commitment to enhancing defense capabilities in Europe [12][15] - THEON Group has a significant global presence, with over 270,000 systems in service across 72 countries, including 26 NATO member countries [17]

We hereby submit the Annual Information of AB Artea Bank for the year 2025, which comprises the audited separate financial statements of the Bank and the audited consolidated financial statements of Artea Bankas AB and its subsidiaries, the independent auditor’s report, the consolidated management report, as well as consolidated information on sustainability together with the independent auditor’s limited assurance report. Additional information:Tomas Varenbergas Chief Financial Officertomas.varenbergas@art ...

Core Insights - The RCI Banque has released its Pillar III Risks Report as of December 31, 2025, which is now accessible on the Mobilize Financial Services website [1] Group 1 - The report provides detailed insights into the risk management framework and capital adequacy of RCI Banque [1] - It highlights the bank's compliance with regulatory requirements and its approach to mitigating various financial risks [1] - The report is part of RCI Banque's commitment to transparency and accountability in its financial operations [1]

Core Viewpoint - Reading International, Inc. reported its financial results for Q4 and the full year 2025, highlighting a decline in cinema revenue but significant improvements in operating income due to strategic initiatives and cost management [5][7][12]. Financial Results - Fourth Quarter 2025 - Total revenues decreased by 14% to $50.3 million compared to $58.6 million in Q4 2024 [7]. - Operating loss was $1.0 million, a decline from operating income of $1.5 million in Q4 2024 [7]. - Net loss increased to $2.6 million from a net loss of $2.2 million in Q4 2024 [7]. - Adjusted EBITDA was $5.1 million, down from $6.8 million in Q4 2024 [7]. - Cinema revenue decreased by 14% to $46.9 million from $54.6 million in Q4 2024 [12]. Financial Results - Full Year 2025 - Total revenue for the year was $203.0 million, down from $210.5 million in 2024 [7]. - Operating loss improved to $5.3 million from an operating loss of $14.0 million in 2024 [7]. - Net loss was $14.1 million, significantly improved from a net loss of $35.3 million in 2024 [7]. - Basic loss per share improved by 60.8% to $0.62 from $1.58 in 2024 [7]. - Full year adjusted EBITDA was $17.8 million, an increase of $15.7 million compared to $2.1 million in 2024 [7]. Cinema Business Performance - Q4 2025 cinema operating income decreased by 76% to $0.9 million from $3.8 million in Q4 2024 [12]. - Full year cinema operating income increased to $3.6 million, up $6.4 million from an operating loss of $2.8 million in 2024 [12]. - The average ticket price reached the highest levels ever recorded in all three markets [12]. - Food and beverage spend per person also set records across all markets [12]. Real Estate Business Performance - The global real estate division reported improved operating income for both Q4 2025 and the full year compared to 2024 [6]. - Q4 2025 real estate revenues decreased to $4.4 million from $5.2 million in Q4 2024 [12]. - Full year real estate revenues decreased by 8% to $18.4 million from $20.0 million in 2024 [12]. Strategic Initiatives - The company sold two international assets in 2025, generating $42.2 million in proceeds, which were used to pay down approximately $32.1 million of bank debt [8][17]. - The company is actively evaluating its asset portfolio for monetization opportunities to reduce interest expenses and improve liquidity [17]. Balance Sheet and Liquidity - As of December 31, 2025, cash and cash equivalents totaled $10.5 million [11]. - Total outstanding secured borrowings were $185.1 million [11]. - The company has engaged in various loan modifications to improve its capital structure and liquidity [17].

Financial Calendar Overview - The financial calendar for the remaining of 2025 and 2026 has been updated, detailing key reporting dates and meetings [1][2]. Key Reporting Dates - Interim report for the period January 1 to September 30, 2025, is scheduled for November 26, 2025 [2]. - The extraordinary general meeting will be held on November 28, 2025 [2]. - The deadline for submission of proposals for voting at the annual general meeting is set for March 23, 2026 [2]. - The Annual Report for 2025 will be published on March 31, 2026 [2]. - The annual general meeting is expected to convene on April 8, 2026, with the actual meeting taking place on April 30, 2026 [2]. - An interim report for the period January 1 to March 31, 2026, is expected on May 29, 2026 [2]. - The half-year report for the period January 1 to June 30, 2026, will be released on August 31, 2026 [2]. - The interim report for the period January 1 to September 30, 2026, is scheduled for November 30, 2026 [2]. Contact Information - Any inquiries regarding the financial calendar can be directed to the provided contact number [2][3].

Core Insights - AerSale Corporation has announced the lease of a Boeing 757-200 Precision Converted Freighter (PCF) to Stratos Freight, an all-cargo airline based in Tashkent, Uzbekistan, enhancing its operational capabilities in the logistics market [1][4]. Company Overview - AerSale is a leading global provider of aviation aftermarket products and services, focusing on integrated solutions for aircraft owners and operators, including MRO services, aircraft and engine sales, and leasing [5]. - Stratos Freight specializes in high-efficiency airfreight services, operating along key trade routes connecting China, the Middle East, and Europe [6]. Strategic Positioning - Stratos Freight is strategically located at the intersection of Asia and Europe, which allows it to operate effectively along major logistics routes [2][6]. - The addition of the Boeing 757-200PCF to Stratos Freight's fleet is expected to enhance its scheduled and charter cargo operations throughout Central Asia and beyond [2]. Aircraft Capabilities - The Boeing 757-200PCF is recognized for its versatility, efficiency, and suitability for regional cargo operations, making it an ideal choice for express and regional missions [3]. - The aircraft's deployment is anticipated to improve connectivity across high-demand trade lanes, emphasizing the importance of efficiency and reliability in cargo operations [3]. Business Model - AerSale's integrated business model leverages its expertise in aircraft leasing, freighter conversions, and asset management to provide value-driven solutions to airline partners globally [4].

Core Insights - Alpha Tau Medical Ltd. has announced that an abstract detailing results from two clinical trials on its alpha-radiation cancer therapy, Alpha DaRT, for pancreatic cancer has been accepted for oral presentation at Digestive Disease Week (DDW) 2026, marking a significant recognition of its technology in a major gastroenterology conference [1][2][3] Company Overview - Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company founded in 2016, focusing on the research, development, and potential commercialization of Alpha DaRT for treating solid tumors [5] - The Alpha DaRT technology was initially developed by Professors Itzhak Kelson and Yona Keisari from Tel Aviv University [5] Technology Details - Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed for highly potent and conformal alpha-irradiation of solid tumors through intratumoral delivery of radium-224 sources, aiming to primarily affect the tumor while sparing surrounding healthy tissue [6] Clinical Trial Presentation - The abstract titled "Updated Results of Feasibility, Safety, and Tumor Control in Two First-In-Human Trials of a Novel Alpha-Emitting Radionuclide for Pancreatic Adenocarcinoma" will be presented on May 2, 2026, at 10:30 am (Central) during the Pancreatic Cancer I: Diagnosis and Treatment session [2] - The presentation will be led by Dr. Harold Jacob, the Principal Investigator, and is based on combined data from two clinical protocols conducted at Hadassah Medical Center in Jerusalem [2] Significance of Presentation - The acceptance of the abstract for oral presentation at DDW is viewed as a milestone for Alpha Tau, indicating growing recognition of the potential of Alpha DaRT to address pancreatic cancer, particularly for patients deemed inoperable at diagnosis [3] - Dr. Jacob emphasized the importance of this presentation as it represents the first clinical data of Alpha DaRT in pancreatic cancer to be shared at a major gastroenterology forum [3]

Core Insights - MAIA Biotechnology, Inc. has reported promising overall survival results for patients treated with ateganosine in its Phase 2 THIO-101 clinical trial for non-small cell lung cancer (NSCLC) [2][4] Company Overview - MAIA Biotechnology is focused on developing targeted immunotherapies for cancer, with its lead program being ateganosine, a first-in-class telomere-targeting agent [8] - The company aims to improve and extend the lives of cancer patients through innovative therapies [8] Clinical Trial Highlights - In the ongoing Phase 2 THIO-101 trial, eight patients have shown overall survival beyond two years without subsequent lines of therapy [2] - The trial has treated a total of 79 patients in Parts A and B, with Part C currently enrolling up to 48 participants in Asia and Europe [2][5] - The treatment regimen of ateganosine followed by cemiplimab has demonstrated an acceptable safety profile in a heavily pre-treated population [2][7] Mechanism of Action - Ateganosine works by targeting telomeres, which are crucial for cancer cell survival and resistance to therapies, leading to selective cancer cell death [4] - The drug induces immune responses that may enhance the effectiveness of subsequent treatments with PD-(L)1 inhibitors [4] Survival Data - One patient in third-line therapy achieved survival of 33 months, while four patients in second-line therapy had survival exceeding 30 months [6] - The expected survival for heavily pre-treated patients is significantly lower, at 5.8 months for standard treatments [6]

Core Viewpoint - T3 Defense Inc. is experiencing a significant increase in business activity and customer engagement, indicating a strengthening pipeline as the company enters an execution phase in the defense sector [1][6]. Business Activity and Demand - The company reported a rise in requests for proposals (RFPs) and inquiries from potential customers across all subsidiaries, reflecting growing demand for integrated defense systems, counter-UAS capabilities, AI-driven security platforms, and advanced engineering services [3][4]. - The increase in engagement is attributed to heightened geopolitical tensions and global investments in defense capabilities, with demand extending beyond OEMs to specialized suppliers and technology providers [2][4]. Subsidiary Performance - T3 Defense's subsidiaries have secured contracts supporting various military applications, showcasing continued strength in defense spending and procurement activity [7]. - Rimon has secured approximately $4.1 million in new multi-year contracts for components related to the Iron Dome missile defense system, highlighting its strategic relevance and technical capabilities [9]. - Tiltan Software Engineering Ltd is experiencing strong demand due to increased adoption of AI and advanced simulation technologies, with interest from both domestic and international customers [8][15]. - Nimbus Drones is witnessing rising demand for advanced drone platforms driven by needs for intelligence, surveillance, and reconnaissance (ISR) capabilities [10]. Market Outlook - The company anticipates further updates as current inquiries are expected to convert into customer engagements and contracts, indicating a positive outlook for sustained growth across its defense technologies [5][6]. - ITS and Positech are also seeing robust demand, with expectations for additional contracts in 2026 as ongoing engagements progress through the procurement cycle [16]. - Zorronet has secured contracts with major Israeli critical infrastructure providers, reflecting a notable increase in inbound customer engagement for integrated situational awareness platforms [16].

Core Insights - NextNRG, Inc. has launched EzShop within its EzFill mobile fueling platform, enabling customers to order over 5,000 everyday essentials alongside fuel delivery through a single app [1][2] - The partnership with Gopuff allows NextNRG to expand its service offerings beyond fueling, creating a new revenue stream while leveraging existing delivery infrastructure [2][3] Company Strategy - The integration with Gopuff is a significant evolution of NextNRG's business model, transitioning from a mobile fueling service to a digital commerce platform that combines energy and convenience [4] - NextNRG aims to create a scalable model that generates additional revenue per delivery and enhances customer relationships [4] Market Expansion - EzShop is set to launch in select EzFill markets in Q2 2026, with plans for further expansion to additional markets by the end of the year [4] - The integration is expected to provide customers with fast delivery of essential products, fulfilling orders in as little as 15 minutes [2][4] Technology and Infrastructure - NextNRG utilizes AI and machine learning to optimize utility infrastructure, battery storage, and mobile fuel delivery, creating a unified platform for modern energy management [5][6] - The company's strategy includes the Next Utility Operating System®, which enhances both new and existing infrastructure across various sectors [6]